From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995

MeSH terms

• Adverse Drug Reaction Reporting Systems*
• Angiotensin-Converting Enzyme Inhibitors / adverse effects*
• Angiotensin-Converting Enzyme Inhibitors / therapeutic use
• Antihypertensive Agents / adverse effects*
• Antihypertensive Agents / therapeutic use
• Canada / epidemiology
• Ductus Arteriosus, Patent / chemically induced
• Female
• Fetal Diseases / chemically induced*
• Fetal Growth Retardation / chemically induced
• Humans
• Hypertension / drug therapy*
• Israel / epidemiology
• Kidney Diseases / chemically induced
• Pregnancy
• Pregnancy Complications, Cardiovascular / drug therapy*
• Pregnancy Outcome
• Pregnancy Trimester, First
• Registries
• United States / epidemiology